Mastering Immunity 6

Monday 11 and Tuesday 12 September, 2017

Museum of Science, Boston, MA

 

Filmed Presentations from all our meetings are available online

Join our Mastering Immunogenicity LinkedIn Group

Understand and manage immune responses in drug and vaccine development

As targeted immune therapies grow in complexity, understanding and controlling immune regulation has never been more important in the design of therapeutics.

Join experts in both academic and commercial immunology at Mastering Immunity 6 for a focussed conference to learn the latest developments in this fast-developing field covering multiple aspects of in the development of modern therapeutics. This focussed meeting is a forum for key people involved in wanting to characterize immune modulation following delivery of biologics and other therapies to come together to share knowledge, perspectives and discuss solutions to the complex challenges of immunity in this context. We will focus on manipulation and characterization of both desired (in immuno-oncology and vaccines) as well as unwanted immune responses (i.e. immunogenicity to biotherapeutics or viral vectors).

This meeting, of which the Mastering Immunogenicity series is part of, is now in its seventh consecutive year having also been held in Boston, USA.  Free access to all recorded talks can be found here.

This year's meeting held at the Museum of Science in Boston offers an unparalleled opportunity to meet and share information with like-minded scientists from other organizations, and to help shape the future of your R&D programs.

Agenda

Day 1: Monday 11 September

8.30am

 

Arrival and registration

8.50am

 

Welcome and conference overview

9.00am

Valerie Quarmby, Director of Dept. of BioAnalytical Sciences, Genentech

"Host Cell Proteins and Immunogenicity"

9.40am

Daron Forman, Principal Scientist, Bristol-Myers Squibb

"The use of immunogenicity risk assessment tools for lead optimization of biologics"

10.20am

Erik Meyer, Senior Scientist, GlaxoSmithKline

"Therapeutic Immunogenicity: Target Interference and Cut Point Evaluation"

11.00am

 

Coffee and Networking

11.30am

Jeremy Fry, Director of Sales, ProImmune

"An integrated approach to managing immunogenicity risk and drug immune modulation"

12.10pm

Laurent Malherbe, Principal Scientist, Non-Clinical Safety Assessment, Eli Lilly

"Post hoc assessment of the immunogenicity of two antibodies using in vitro assays reveals distinct immunostimulatory mechanisms"

12.50pm

 

Lunch

1.50pm

Priya Sriraman, Director, Biologics DMPK, Celgene

"Approaches to identify immunogenic epitopes to support de-immunization of biologics"

2.30pm

Wojciech Jankowski, Research Reviewer, CBER, FDA

"Non-clinical Assessments of Immunogenicity"

3.10pm

 

Coffee and networking

3.40pm

Eric Zanelli, Head of R&D, Déclion Holdings

"DP-C016, a phosphoTau vaccine for the treatment of tauopathies"

4.20pm

Jiang Wu, Associate Director of Global BioAnalytical Development, Shire

"Reagent-free LC-MS Assay to Measure PK Profiles of ADA+ Patients"

5.00-6.30

 

Drinks reception

Day 2: Tuesday 12 September

8.30am

 

Arrival and registration

9.00am

Gijsbert Grotenbreg, Snr Dir Experimental Immunology, Gritstone Oncology, Inc.

"Optimizing vaccine design to drive potent T-cell responses for personalized neoantigen immunotherapy"

9.40am

Nik Schwabe, CEO, ProImmune

"Epitope identification and clinical immune monitoring in immune oncology programmes"

10.20am

 

Coffee and Networking

10.50am

Gary Means, Associate Director, Diagnostics & Biomarkers, Seattle Genetics

"Biomarkers of immunological responses in patients with solid tumor cancers treated with a CD40 agonist, SEA-CD40"

11.30am

Govinda Sharma, PhD Student, British Columbia Cancer Agency

"Functional identification of CD8+ T cell epitopes by parallel interrogation of more than a million distinct peptide-coding sequences"

12.10pm

 

Lunch

1.00pm

Ryan Sullivan, Investigator, Novartis Institutes for Biomedical Research

"Characterizing tumor-specific CD8+ T cells within the tumor microenvironment of syngeneic mouse models to guide therapeutic strategies"

1.40pm

Scott McClain, Product Safety Expert, Syngenta Crop Protection

"Bioinformatic screen and detection of immunologically relevant cross-reactive IgE-binding epitopes"

2.20pm

 

Coffee and networking

2.40pm

Christine Shaw, Director of Immunology, Valera/Moderna

"mRNA vaccines: a platform to induce protective immunity against infectious diseases"

3.20pm

 

Christopher Harvey, Jounce Therapeutics

"Preclinical safety assessment of JTX-2011 in support of first-in-human dosing in the ICONIC trial"

4.00pm

 

Close of meeting

 

  Speaker Information

 

Dr. Valerie Quarmby

Director of Dept. of BioAnalytical Sciences, Genentech

 

Valerie Quarmby is a Staff Scientist in the Department of BioAnalytical Sciences at Genentech. At Genentech, Dr. Quarmby has developed bioanalytical methods & strategies to enable IND, BLA and related filings for: Nutropin, Xolair, Raptiva, Rituxan, Avastin, Lucentis, Perjeta, Kadcyla and Tecentriq. She has also developed bioanalytical methods, platforms and strategies for many of the therapeutic proteins in the gRED drug development pipeline. Valerie also consults on bioanalytical and related strategies across the Roche group. She is the past Chair of the AAPS Therapeutic Protein Immunogenicity Focus Group and a member of the 2010-2015 USP Immunogenicity Testing Expert Panel. Valerie is the co-author of several AAPS sponsored industry guidance documents and many publications in peer-reviewed journals. Valerie Quarmby holds a Ph.D. in Hormone Physiology from the Imperial Cancer Research Fund and the University of London in England. Dr. Quarmby was a Postdoctoral Visiting Fellow at the US National Institutes of Health, and then joined the Laboratories for Reproductive Biology and the Department of Pediatric Endocrinology at UNC-Chapel Hill. Prior to joining Genentech, Dr. Quarmby worked in the field of clinical diagnostics at Bio-Rad Laboratories and at Endocrine Sciences/Esoterix. In 2014, in recognition of her many contributions to the pharmaceutical industry, Dr. Quarmby was awarded AAPS Fellow Status.

                 Daron Forman  

Principal Scientist, Bristol-Myers Squibb

Daron Forman graduated from the University of Rochester  with a double B.A. in biology and in psychology. He received his Ph.D. in Virology/Immunology from the University of Massachusetts Medical School in Worcester and performed his post-doctoral studies in Dr. Iacomini’s laboratory at Mass General Hospital/Harvard. Dr. Forman has spent over 18 years working on various therapeutic proteins in both academia and industry. Prior to BMS, Dr. Forman was with Tolerx, where he investigated the mechanism of action and potential biomarkers for several therapeutic Abs, including anti-CD3 and anti-GITR mAbs.  Dr. Forman joined Bristol-Myers Squibb in 2009, and his current responsibilities as Principal Scientist for their Immunogenicity Prediction Core include in silico, in vitro and in vivo evaluation of therapeutic proteins for clinical immunogenicity risk assessment. 

 

                 Erik Meyer  

Senior Scientist, GlaxoSmithKline

Erik Meyer’s formal education included undergraduate studies at the University of Texas in Austin, graduate studies at Massachusetts Institute of Technology, and post-doctoral work at Texas A&M.  I then joined a biotech start up, Xenomics isolating urine DNA for diagnostic analysis. At Huntingdon Life Sciences and Tandem Laboratories, I learned the nuances of Good Laboratory Practices and immune assay development for PK and immunogenicity detection, which have been useful for supporting anti-drug antibody detection for various clinical projects at GSK. 

 

 

 

                 Jeremy Fry  

Director of Sales, ProImmune

Jeremy Fry gained his DPhil. from the University of Oxford developing gene therapy strategies to induce immunological tolerance in transplant recipients. Jeremy joined ProImmune to generate a new class of MHC multimer staining reagents. For the past 14 years as ProImmune's Director of Sales, he has led the sales team in a growing business, focusing on technologies that radically improve our understanding of immune responses.

 

 

 

 

 

Laurent Malherbe  

Principal Scientist, Non-Clinical Safety Assessment, Eli Lilly

Laurent Malherbe is a Principal Research Scientist in the ADME, Toxicology and PK/PD (ATP) organization at Eli Lilly and Company. He received his PhD in Immunology in 2001 from the University of Nice Sophia-Antipolis (Nice, France) and completed in 2017 his postdoctoral training with Michael McHeyzer-Williams at the Scripps Research Institute (La Jolla, CA). From 2007 to 2014 he worked at the Blood Research Institute, BloodCenter of Wisconsin (Milwaukee, WI) as a principal investigator studying the mechanisms regulating CD4 T cell responses following infection and vaccination. At Eli Lilly, Laurent leads a laboratory responsible for the preclinical immunosafety risk assessment of biotherapeutics.

 

 

 

Priya Sriraman

Director, Biologics DMPK, Celgene

Priya Sriraman is currently Director - Biologics Development, at Celgene in NJ. Her group is responsible for immunogenicity, bioanalytical and pharmacokinetic evaluations for biologics and cell therapy programs, and support discovery, preclinical and clinical development.  Prior to Celgene, Priya was at Roche Pharmaceuticals in Nutley NJ for 8 years, supporting biologics development.

 

 

 

 

Wojciech Jankowski

Research Reviewer, CBER, FDA

Dr. Jankowski is a research reviewer with the US Food and Drug Administration. He is part of an active research laboratory and his research interests lie in the regulatory-science associated with the licensure of the next generation of therapeutic proteins. A key focus of his research activities has been to understand the immune response to protein therapeutics, which can significantly affect the efficacy and safety of these drugs. He uses a combination of computational, in vitro and ex vivo approaches in his work. Dr. Jankowski received his Ph.D. from Rutgers University, NJ and was subsequently selected for the highly competitive Commissioner’s Fellowship program at the FDA. His research has been published in high impact journals such as Nature and Nature Chemical Biology.

 

Eric Zanelli

Head of R&D, Déclion Holdings

 

Eric Zanelli, Head of R&D and Scientific Founder of Déclion Holdings LLC, has been interested in peptide vaccines and immunomodulators for the last 25 years. His previous positions include Head of R&D at Peptimmune Inc., Senior Scientist at Praecis Pharmaceuticals and Cardion AG, and Senior Investigator at Leiden University Medical Center. He completed his postdoctoral training at the Mayo Clinic in Rochester MN in the laboratory of Dr. Chella David, a pioneer in the field of Immunogenetics.

 

 

 

 

 

Jiang Wu

Associate Director of Global BioAnalytical Development, Shire

Jiang Wu is an associate director of global bioanalytical and biomarker development at Shire, responsible for development and validation of regulated PK and biomarker assays in support of nonclinical, clinical, and commercial programs across company’s portfolios. Prior to Shire, he was an associate research fellow at Pfizer worldwide medicinal chemistry division and a lab head at Wyeth biotherapeutics division, where his team utilized a variety of techniques to identify and validate novel drug targets, biomarkers, and drug MOA for different drug modalities targeting cardiovascular diseases, inflammation, rare and orphan diseases, and cancer.  He also worked as a biomarker group lead at Millennium Pharmaceuticals and a senior scientist at Abbott.  He has authored 60 scientific papers, book chapters, and patents.

 

Gijsbert Grotenbreg

Senior Director of Experimental Immunology, Gritstone Oncology, Inc.

Dr. Gijsbert Grotenbreg is Senior Director of Experimental Immunology at Gritstone Oncology Inc., He combines 18 years of experience in the fields of chemistry and immunology, with a focus on antigen processing and presentation, major histocompatibility complex (MHC) biology, and cellular immunology. Prior to joining Gritstone Oncology, Dr Grotenbreg was Head of Diagnostics Discovery at 121Bio LLC, held an assistant professorship at the Department of Microbiology and the Immunology Programme of the National University of Singapore, and was recipient of the Singapore NRF Research Fellowship. He was awarded his PhD degree Cum Laude in synthetic organic chemistry from Leiden University, and performed postdoctoral research at Harvard Medical School, the Whitehead Institute for Biomedical Research, and the Massachusetts Institute of Technology.

Dr. Nikolai Schwabe

CEO, ProImmune

Nik Schwabe has the responsibility is the day-to-day management of ProImmune’s business. Prior to founding ProImmune together with Linda Tan in 2000, Nik worked in a variety of management positions in the fiber-optics industry and in investment banking. Nik holds a D.Phil. in Theoretical Physics from Oxford University.

 

 

 

 

 

Gary Means

Associate Director, Diagnostics & Biomarkers, Seattle Genetics

Gary Means has specialized in the discovery and strategic development of biomarker assays for clinical studies for almost two decades.  His overall experience has spanned two broad therapeutic areas- inflammatory diseases and cancer.  This has afforded him the opportunity to explore biomarkers and to gain data-driven insights over a wide range of therapeutic modalities from precision medicine to antibody-drug conjugates and immuno-oncology therapies.  Gary held positions at Immunex and Amgen prior to his current role as an Associate Director in the Diagnostics and Biomarkers group at Seattle Genetics.

 

 

 

Govinda Sharma

PhD Student, British Columbia Cancer Agency

Govinda Sharma is originally from Calgary, Canada, and obtained his B.Sc. (2010) in Molecular Biology & Biochemistry from Simon Fraser University in Burnaby, British Columbia, Canada. After spending 2 years working in industry, he began graduate studies in the Genome Science + Technology Program at the University of British Columbia in 2012. He is currently in the 5th year of his PhD working under Dr. Robert Holt at the Michael Smith Genome Sciences Centre, a department of the British Columbia Cancer Agency, located in Vancouver, British Columbia, Canada.

 

 

 

Ryan Sullivan

Investigator, Novartis Institutes for Biomedical Research

Ryan Sullivan is currently an Investigator in Exploratory Immuno-Oncology at the Novartis Institutes for Biomedical Research, where his work focuses on cytotoxic NK and CD8+ T cells in the context of immunotherapy. Ryan earned his undergraduate degree from Michigan State University, where he was an Alumni Distinguished Scholar (full-tuition academic scholarship) and recipient of the Sayer Award for academic excellence, and his Ph.D. from Washington University in St. Louis, where he studied the function of microRNAs in NK cell activation and maturation under Dr. Todd Fehniger. Ryan’s post-doctoral work at the Dana-Farber Cancer Institute, under the direction of Glenn Dranoff, focused on NK cells and CD8+ T cells in the context of the anti-tumor immune response. Ryan’s work has been published in PNAS, Journal of Immunology, Blood, Genome Research, and Journal of Clinical Investigation.

Scott McClain

Product Safety Expert, Syngenta Crop Protection

Scott McClain’s academic background is in behavioral and molecular toxicology having received his M.S. and Ph.D. degrees in the Center for Environmental Toxicology and Statistics at Miami University, in Oxford, OH.  Dr. McClain’s professional background is in the biotechnology sector with training primarily in immunology, clinical allergy diagnostics, product efficacy and safety testing.  He started his professional career supporting research programs in immunology and biochemistry with a focus on developing bioactive food ingredients.  The last 12 years have been in the regulatory divisions of the agricultural biotechnology sector with an emphasis on conducting and communicating risk assessments in allergy and toxicology which support the safe introduction of novel food and feed crop products.  Dr. McClain has worked in Syngenta Product Safety for 8 years.  He represents Syngenta as co-chair of the ILSI/HESI Protein Allergenicity Technical Committee and Chair of the Crop Life International Allergy Expert Team.

Christine Shaw

Director of Immunology, Valera/Moderna

Christine Shaw is the Director of Immunology of Valera, a fully owned venture of Moderna that focuses on the discovery of vaccines and therapeutics for infectious diseases using Moderna’s mRNA technology.  Prior to joining Valera in 2015, she spent 8 years at Novartis Vaccines evaluating a variety of candidate vaccines in preclinical models. Christine holds a PhD in Microbiology and Molecular Genetics from Harvard University.

 

Christopher Harvey

Head of Preclinical Bioassays, Jounce Therapeutics

Christopher Harvey is a Principal Scientist and Head of Preclinical Bioassays at Jounce Therapeutics in Cambridge, MA.  He was one of the lead scientists involved in the preclinical development and safety assessment of JTX-2011, overseeing the IND enabling studies to support the initiation of the first-in-human Phase I/II trial.  Chris’ group currently is involved in the continued development of JTX-2011 as well as supporting development activities of other Jounce pipeline programs. 

Chris received his B.S. from Georgetown University and his Ph.D. from Johns Hopkins University prior to pursuing post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.

How will I benefit?

  • Education

    • Learn the key issues facing drug developers

    • Be informed of the latest strategies for pre-clinical and clinical immune modulation

    • Quality by Design in drug development

    • Be informed of the latest technologies to keep ahead of the competition

    • Case studies

  • Network

    • Exchange new ideas

    • Meet potential collaborators

    • Discuss current and developing challenges

    • Meet like-minded scientists from other organizations, and to help shape the future of your own R&D programs.

Feedback from previous conferences:

“I enjoyed this meeting very much. You really succeed to gather very diverse aspects of immunogenicity and many of the presentation were completely new for me. It was also a nice opportunity to meet new people. Congratulations! ” (Bernard Maillère, CEA)

“It was an excellent meeting, very interesting and very well organized. I enjoyed it a lot.” (Petra Luehrs, AFFiRiS)

“Mastering Immunogenicity captured the breadth and depth of immunogenicity issues faced by industry today” (Tim Hickling, Pfizer)

“I also had a great time during the meeting. It was truly excellent in content and organization.” (Julio Delgado, University of Utah)

“It was a terrific event, with excellent speakers and great networking/brainstorming opportunities at the breaks and with the roundtable” (Valerie Quarmby, Genentech)

"Great first experience. I enjoyed the breadth of topics" (Laurent Malherbe, Eli Lilly)

 “Great speakers with diverse topics. I enjoyed the deep science and also the opinions from experts in the field” (Xiaoying Chen, Pfizer)

 "Covered a diverse array of subjects. I enjoyed the networking opportunities” (Shinu John, Moderna Therapeutics)

"Excellent event" (George Gunn, Janssen R&D)

"Really liked the interactive environment. In-depth discussions with very relevant colleagues"

 "I really enjoyed the very good quality, sparkling diversity, but still keeping focus"

Conference Venue

Boston Museum of Science, 1 Science Park, Boston, MA 02114

The city of Boston is an international center of higher education and a center for medicine and biotechnology, and consequently is a fitting location for ProImmune's Mastering Immunity conference. This year, the venue is the Museum of Science, one of the world's largest science centers, and New England's most highly attended cultural institution.

The meeting will take place in the Skyline Room on the Museum's top floor, with panoramic views of the Charles River, Back Bay, Boston and Cambridge through two walls of floor-to-ceiling windows.

 

Accommodation
Delegates are responsible for arranging their own accommodation. The following are suggested options for accommodation in the vicinity of the conference venue:

Royal Sonesta Hotel: http://sonesta.com/corporate
Kimpton Hotel Marlowe: http://www.hotelmarlowe.com

Fairfield Inn & Suites by Marriott: http://www.mariott.com 

Hotel Marlowe: http://www.hotelmarlowe.com
Hampton Inn Boston Cambridge:
http://hamptoninn3.hilton.com

Transportation
For drivers: Delegates are offered free parking validation at the Museum Car Park.

For rail users: the closest T stop is 'Science Park' on the Green Line (4 min walk); for the Red Line use 'Kendall Square' (20 min walk).

 

For all Conference Enquiries please contact:

enquiries@proimmune.com

Telephone (toll free): USA & Canada +1 888 505 7765
All other countries +44 (0) 870 042 7279